Dicerna escalates war with Alnylam over RNAi secrets, claiming its rival wants a monopoly
Alnylam made quite a splash in early 2014 when it announced that it had acquired Merck’s RNAi subsidiary Sirna for $175 million. The deal to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
